Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced 24 April 2018
1 Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy 24 April 2018
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States 24 April 2018
Helsinn Group to Present a Poster at Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018 24 April 2018
Cerbios-Pharma SA – Enterococcus faecium SF68®: a model for efficacy and safety for Pharmaceutical Probiotics 20 April 2018
Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care 12 April 2018
Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal 4 April 2018
Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced 28 March 2018
Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards 26 March 2018
1 Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer 20 March 2018
Linkedin